• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ITCI

    Intra-Cellular Therapies Inc.

    Subscribe to $ITCI
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

    IPO Year:

    Exchange: NASDAQ

    Website: intracellulartherapies.com

    Peers

    $FGEN

    Recent Analyst Ratings for Intra-Cellular Therapies Inc.

    DatePrice TargetRatingAnalyst
    2/24/2025$140.00 → $132.00Outperform → Neutral
    Mizuho
    1/31/2025$119.00 → $132.00Buy → Hold
    Canaccord Genuity
    9/6/2024$68.00 → $92.00Neutral → Overweight
    Piper Sandler
    1/3/2024$83.00Outperform
    Robert W. Baird
    12/11/2023$75.00Outperform
    TD Cowen
    4/20/2023$80.00Overweight
    Morgan Stanley
    8/22/2022$64.00 → $49.00Buy → Neutral
    Goldman
    7/7/2022$74.00Buy
    Mizuho
    6/14/2022$75.00Buy
    UBS
    4/22/2022$59.00Neutral
    Piper Sandler
    See more ratings